Correlation between Myeloperoxidase and Interleukin-6 of Patients with Obstructive Sleep Apnea Syndrome in Thi-Qar Governorate
DOI:
https://doi.org/10.32792/utq/utjsci/v11i2.1253Abstract
Abstract
This research aimed to detect the relationship between Myeloperoxidase (MPO) and Interleukin-6 (IL-6) in patients obstructive sleep apnea syndrome (OSAS). The present study has been conducted on a number of healthy people and patients. Group A: 84 patients Obstructive sleep apnea syndrome (mild, mod and sever) with high blood pressure [47 male, 37 female] and age range (40 - 65). Group B: control group, consist of 64 healthy people [33 male, 31 female] and age range (40 - 65). The findings from the current research indicated a notable rise in levels of serum MPO and serum IL-6 among patient groups when compared with the control group (P≤0.05). Results indicated that there was a positive correlation between MPO with IL-6 in patients with OSAS. OSA patients show high serum myeloperoxidase and serum interleukin-6 concentrations, which signal heightened systemic inflammation and oxidative stress. These factors, part of the pathogenesis of cardiovascular disease are important risk predictors to measure in OSA patients: this can be helpful for early diagnosis of the disease.
Received: 2024-05-15
Revised: 2024-06-27
Accepted: 2024-07-19
References
[1] S. Gresova et al., "An Obstructive Sleep Apnea-A Novel Public Health Threat," Physiological Research, vol. 72, no. 4, p. 415, 2023.
[2] S. P. Gunta et al., "Obstructive sleep apnea and cardiovascular diseases: sad realities and untold truths regarding care of patients in 2022," Cardiovascular Therapeutics, vol. 2022, no. 1, p. 6006127, 2022.
[3] C. Arnaud, M. Dematteis, J.-L. Pepin, J.-P. Baguet, and P. Lévy, "Obstructive sleep apnea, immuno-inflammation, and atherosclerosis," in Seminars in immunopathology, 2009, vol. 31: Springer, pp. 113-125.
[4] P. Lévy, J.-L. Pépin, C. Arnaud, J.-P. Baguet, M. Dematteis, and F. Mach, "Obstructive sleep apnea and atherosclerosis," Progress in cardiovascular diseases, vol. 51, no. 5, pp. 400-410, 2009.
[5] W. T. McNicholas, "Obstructive sleep apnea and inflammation," Progress in cardiovascular diseases, vol. 51, no. 5, pp. 392-399, 2009.
[6] B. D. Kent, S. Ryan, and W. T. McNicholas, "Obstructive sleep apnea and inflammation: relationship to cardiovascular co-morbidity," Respiratory physiology & neurobiology, vol. 178, no. 3, pp. 475-481, 2011.
[7] W.-Q. Liu et al., "Myeloperoxidase-derived hypochlorous acid promotes ox-LDL-induced senescence of endothelial cells through a mechanism involving β-catenin signaling in hyperlipidemia," Biochemical and biophysical research communications, vol. 467, no. 4, pp. 859-865, 2015.
[8] A. A. Khan, A. H. Rahmani, Y. H. Aldebasi, and S. M. Aly, "Biochemical and pathological studies on peroxidases–An updated review," Global journal of health science, vol. 6, no. 5, p. 87, 2014.
[9] S. J. Nicholls and S. L. Hazen, "Myeloperoxidase and cardiovascular disease," Arteriosclerosis, thrombosis, and vascular biology, vol. 25, no. 6, pp. 1102-1111, 2005.
[10] Y. Chen, N. Hashiguchi, L. Yip, and W. G. Junger, "Hypertonic saline enhances neutrophil elastase release through activation of P2 and A3 receptors," American Journal of Physiology-Cell Physiology, vol. 290, no. 4, pp. C1051-C1059, 2006.
[11] I. Naegelen, N. Beaume, S. Plançon, V. Schenten, E. J. Tschirhart, and S. Bréchard, "Regulation of neutrophil degranulation and cytokine secretion: a novel model approach based on linear fitting," Journal of immunology research, vol. 2015, no. 1, p. 817038, 2015.
[12] A. A. Khan, M. A. Alsahli, and A. H. Rahmani, "Myeloperoxidase as an active disease biomarker: recent biochemical and pathological perspectives," Medical sciences, vol. 6, no. 2, p. 33, 2018.
[13] A. L. Chapman, O. Skaff, R. Senthilmohan, A. J. Kettle, and M. J. Davies, "Hypobromous acid and bromamine production by neutrophils and modulation by superoxide," Biochemical Journal, vol. 417, no. 3, pp. 773-781, 2009.
[14] M. J. Davies, C. L. Hawkins, D. I. Pattison, and M. D. Rees, "Mammalian heme peroxidases: from molecular mechanisms to health implications," Antioxidants & redox signaling, vol. 10, no. 7, pp. 1199-1234, 2008.
[15] J. Wolf, S. Rose-John, and C. Garbers, "Interleukin-6 and its receptors: a highly regulated and dynamic system," Cytokine, vol. 70, no. 1, pp. 11-20, 2014.
[16] D. Gozal et al., "Visceral white adipose tissue after chronic intermittent and sustained hypoxia in mice," American journal of respiratory cell and molecular biology, vol. 56, no. 4, pp. 477-487, 2017.
[17] V. A. Poroyko et al., "Chronic sleep disruption alters gut microbiota, induces systemic and adipose tissue inflammation and insulin resistance in mice," Scientific reports, vol. 6, no. 1, p. 35405, 2016.
[18] W.-Y. Lee, M. A. Allison, D.-J. Kim, C.-H. Song, and E. Barrett-Connor, "Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho
Bernardo Study)," The American journal of cardiology, vol. 99, no. 1, pp. 99-102, 2007.
[19] S. Sirpal, "Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease," Clinical Science, vol. 116, no. 9, pp. 681-695, 2009.
[20] K. Yonezawa et al., "Significance of the neutrophil myeloperoxidase index in patients with atherosclerotic diseases," The Kobe journal of the medical sciences, vol. 58, no. 5, pp. 128-137, 2012.
[21] K. Yonezawa et al., "Significance of the neutrophil myeloperoxidase index in patients with atherosclerotic diseases," The Kobe journal of the medical sciences, vol. 58, no. 5, pp. 128-137, 2012.
[22] W. W. Tang, Y. Wu, S. J. Nicholls, and S. L. Hazen, "Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease," Clinical chemistry, vol. 57, no. 1, pp. 33-39, 2011.
[23] M. C. Meuwese et al., "Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study," Journal of the American College of Cardiology, vol. 50, no. 2, pp. 159-165, 2007.
[24] F. Hanikoglu, N. Huseyinoglu, S. Ozben, A. Cort, S. Ozdem, and T. Ozben, "Increased plasma soluble tumor necrosis factor receptor-1 and myeloperoxidase activity in patients with obstructive sleep apnea syndrome," International Journal of Neuroscience, 125(9), 655-662, 2015.
[25] A. A. Naji and H. M. Mousa, "Evaluation of Interleukin6 (IL-6) levels in Atopic Dermatitis Patients in Thi-Qar province," University of Thi-Qar Journal of Science, vol. 9, no. 1, pp. 49-51, 2022. https://doi.org/10.32792/utq/utjsci.v9i1.876.
[26] E. Lindmark, E. Diderholm, L. Wallentin, and A. Siegbahn, "Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy," Jama, vol. 286, no. 17, pp. 2107-2113, 2001.
[27] P. M. Ridker, N. Rifai, M. J. Stampfer, and C. H. Hennekens, "Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men," Circulation, vol. 101, no. 15, pp. 1767-1772, 2000.
[28] T. U. Ciftci, O. Kokturk, N. Bukan, and A. Bilgihan, "The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome," Cytokine, vol. 28, no. 2, pp. 87-91, 2004.doi:10.1016/j. cyto. 2004.07.003, 2004.
[29] E. Kasasbeh, D. S. Chi, and G. Krishnaswamy, "Inflammatory aspects of sleep apnea and their cardiovascular consequences," Southern medical journal, vol. 99, no. 1, pp. 58-68, 2006. doi:10.1097/01.smj.0000197705.99639.50, 2006.
[30] M. M. Imani, M. Sadeghi, H. Khazaie, M. Emami, D. Sadeghi Bahmani, and S. Brand, "Evaluation of serum and plasma interleukin-6 levels in obstructive sleep apnea syndrome: a meta-analysis and meta-regression," Frontiers in immunology, vol. 11, p. 1343, 2020.
[31] D. A. Papanicolaou, "Interleukin-6: the endocrine cytokine," The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 3, pp. 1331-1333, 2000.
[32] A. N. Vgontzas, D. A. Papanicolaou, E. O. Bixler, A. Kales, K. Tyson, and G. P. Chrousos, "Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity," The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 5, pp. 1313-1316, 1997. doi: 10.1210/jcem.82.5.3950, 1997.
[33] A. N. Vgontzas et al., "Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia," The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 3, pp. 1151-1158, 2000. doi: 10.1210/jcem.85.3.6484, 2000.
[34] E. O. Bixler, A. N. Vgontzas, H.-M. Lin, S. L. Calhoun, A. Vela-Bueno, and A. Kales, "Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression," The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 8, pp. 4510-4515, 2005. doi: 10.1210/jc.2005-0035, 2005.
[35] G. Trakada, G. P. Chrousos, S. Pejovic, and A. N. Vgontzas, "Sleep apnea and its association with the stress system, inflammation, insulin resistance and visceral obesity," Sleep medicine clinics, vol. 2, no. 2, pp.251-261, 2007. https://doi: 10.1016/j.jsmc.2007.04.003, 2007.
[36] Y. Dowlati et al., "A meta-analysis of cytokines in major depression," Biological psychiatry, vol. 67, no. 5, pp. 446-457, 2010. https://doi: 10.1016/j.biopsych.2009. 09.033, 2010.
Downloads
Published
License
Copyright (c) 2024 University of Thi-Qar Journal of Science
This work is licensed under a Creative Commons Attribution 4.0 International License.
